| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C22H22N4O2 |
| Molar mass | 374.444 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
OPK-88004 (formerly known asLY-2452473 orTT-701) is a non-steroidalindole derivative which acts as aselective androgen receptor modulator (SARM). It has been investigated byOPKO Health for the treatment oferectile dysfunction and symptoms associated withbenign prostate hyperplasia.[1][2][3]
The compound advanced to a phase II trial inbenign prostatic hyperplasia, but it was terminated due to difficulty in measuring prostate size, the trial's primary endpoint.[4]
It was also tried in a study to improve quality of life in patients withprostate cancer. Although it did not cause progression of the disease and increasedlean body mass, the drug did not improve sexual function.[3]
Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |